

**Sun Pharmaceutical Industries Limited**

Sun House, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai – 400 063, Maharashtra, INDIA.  
Tel.: (91-22) 4324 4324  
Fax: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



01 December 2025

**National Stock Exchange of India Limited**  
Scrip Symbol: SUNPHARMA

**BSE Limited**  
Scrip Code: 524715

**Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Press Release**

---

Enclosed herewith is a copy of the press release by Sun Pharmaceutical Industries Limited (together with its subsidiaries / associate companies, “Sun Pharma introduces its global innovative drug, Ilumya® in India for treatment of moderate-to-severe Plaque Psoriasis”

For **Sun Pharmaceutical Industries Limited**

(Anoop Deshpande)  
**Company Secretary and Compliance Officer**  
ICSI Membership No.: A23983



FOR IMMEDIATE RELEASE

## Sun Pharma introduces its global innovative drug, Ilumya® in India for treatment of moderate-to-severe Plaque Psoriasis

**MUMBAI, India, December 01, 2025** – Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the launch of its global innovative drug, ILUMYA (Tildrakizumab) in India for moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA has been endorsed widely by dermatologists in the US and worldwide for several years as an effective and safe treatment of moderate to severe plaque psoriasis.

“ILUMYA offers a safe and effective treatment option for patients who are struggling to manage their moderate-to-severe plaque psoriasis,” said Kirti Ganorkar, Managing Director, Sun Pharma. “We are pleased to introduce this novel therapy in India from our global portfolio of innovative medicines. Already available in 35 countries, ILUMYA has consistently demonstrated significant and long-lasting skin clearance, beginning soon after initiation and sustained over years.”

Sun Pharma’s clinical study in India included 115 patients of moderate-to-severe plaque psoriasis. A 75 percent skin clearance ( $\geq 75\%$  reduction in Psoriasis Area Severity Index Score) was seen in 62.3%, 83.3% and 93.9% patients, respectively at Weeks 12, 16, 28. A 90 percent skin clearance ( $\geq 90\%$  reduction in Psoriasis Area Severity Index Score) was seen in 26.3%, 50%, & 78.1% patients, respectively at Week 12, 16 & 28. Patients received 3 subcutaneous injections of Tildrakizumab over a period of 16 Weeks (Day 1, Week 4 & Week 16) and were followed for a period of 28 weeks. Significant improvements were also observed on additional efficacy endpoints such as, Dermatology Life Quality Index (DLQI) score. Tildrakizumab was well tolerated by Indian patients, with no immunogenicity concerns observed in this study.

“Having been involved in the clinical development of Tildrakizumab in India, I am pleased to see its potential as an effective, safe, and long-lasting treatment for psoriasis. In the Phase-3 trial, tildrakizumab demonstrated significant improvements across all measures, with approximately 93.5% reduction in PASI score and pronounced skin clearance.” said Dr. B. S. Chandrashekar, Chief Dermatologist and Managing Director at Cutis Academy of Cutaneous Sciences, Bengaluru, India who was also an investigator in India Phase 3 trial. “These results showcase its benefits in improving the quality of life for psoriasis patients.”

ILUMYA is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials in moderate-to-severe plaque psoriasis<sup>9</sup>. Patients living with moderate-to-severe plaque psoriasis need therapies they can use over long periods of time without loss of efficacy, and data shows that ILUMYA is a sustainable choice for patients over the long term.



## About Plaque Psoriasis

Plaque psoriasis is a chronic autoimmune disease that causes the cells to reproduce very quickly. It's a type of psoriasis that causes thick, scaly patches called plaques on the skin. The global psoriasis prevalence rate is around 2–3% of the world population <sup>[1]</sup> whereas in India the prevalence varies from 0.44–2.8% <sup>[2]</sup>. Psoriasis is now recognised as a chronic, systemic immune-mediated disease associated with metabolic and cardiovascular comorbidities that markedly impair patients' physical, psychological and social quality of life <sup>[3–5]</sup>. Despite this burden, many Indian patients remain inadequately controlled on traditional systemic therapies or older biologics due to limited long-term efficacy, safety and tolerability concerns, cumulative toxicity, monitoring requirements and treatment fatigue — a challenge highlighted in surveys of Indian dermatologists and patients <sup>[6]</sup>. This leads to persistent inflammation, recurrent flares and under-addressed comorbidity risks <sup>[7,8]</sup>. Consequently, there is a clear unmet need for targeted therapies that deliver high, sustained skin clearance with favourable safety, minimal monitoring burden and simplified dosing to support durable disease control and improve overall quality of life for Indian patients <sup>[6]</sup>.

## About ILUMYA®

ILUMYA (tildrakizumab-asmn) is a humanized IgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23 (IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. ILUMYA<sup>TM</sup> is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. The U.S. Food and Drug Administration approval is based on data from the pivotal Phase-3 reSURFACE clinical development program, which consisted of two randomized, double-blind, placebo-controlled trials of more than 1,800 patients across over 200 clinical trial sites.

## References

1. Damiani G, Bragazzi NL, Karimkhani Aksut C, Wu D, Alicandro G, McGonagle D, Guo C, Dellavalle R, Grada A, Wong P, La Vecchia C, Tam LS, Cooper KD, Naghavi M. The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study. *Front Med (Lausanne)*. 2021 Dec 16;8:743180
2. Dogra S, Yadav S. Psoriasis in India: prevalence and pattern. *Indian J Dermatol Venereol Leprol*. 2010;76(6):595–601.
3. Armstrong AW, Read C. Pathophysiology, clinical presentation, and comorbidities of psoriasis. *Lancet*. 2020;395(10228):130–140.
4. Chandrashekar BS, Nayak CS, Kar BR, Salloju V. Patient perspectives on the impact of psoriatic disease on quality of life in India: a sub-analysis from the Global Psoriasis and Beyond Survey. *Indian Dermatol Online J*. 2024;15(6):1–7.
5. Singh G, Aneja SP. Cardiovascular comorbidity in psoriasis: insights from Indian patients. *Indian J Dermatol*. 2011;56(5):553–556.
6. Rajagopalan M, Dogra S, Godse K, et al. Therapeutic inertia in the management of psoriasis: a quantitative survey among Indian dermatologists and patients. *Psoriasis Targets Ther*. 2022;12:221–230.
7. Sureja RB, Sureja JB, Pipalia MR, Sureja BR. Systemic inflammatory markers and cardiovascular risk in psoriasis. *J Popul Ther Clin Pharmacol*. 2025;32(7):919–923.
8. Dahiya T, Meena BS, Chaudhary S. Metabolic syndrome and subclinical cardiovascular disease in psoriasis. *J Heart Valve Dis*. 2025;30(8):316–319
9. Thaci D., et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomised Phase 3 clinical trials (reSURFACE 1 and reSURFACE 2) through 5 years. Presented at 2020 EADV Virtual Congress, October 2020.

Sun Pharmaceutical Industries Limited  
SUN HOUSE, Plot No. 201 B/1,  
Western Express Highway, Goregaon (E),  
Mumbai 400063, India  
Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343  
Website: [www.sunpharma.com](http://www.sunpharma.com)  
Email: [secretarial@sunpharma.com](mailto:secretarial@sunpharma.com)  
CIN: L24230GJ1993PLC019050



### **Disclaimer**

Statements in this “Document” describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

### **About Sun Pharmaceutical Industries Limited. (CIN - L24230GJ1993PLC019050)**

Sun Pharma is the world’s leading specialty generics company with a presence in specialty, generics and consumer healthcare products. It is the largest pharmaceutical company in India and is a leading generic company in the U.S. as well as global emerging markets. Sun Pharma’s high-growth global specialty portfolio spans innovative products in dermatology, ophthalmology, and onco-dermatology and accounts for about 20% of company sales. The company’s vertically integrated operations deliver high-quality medicines, trusted by physicians and consumers in over 100 countries. Its manufacturing facilities are spread across six continents. Sun Pharma is proud of its multicultural workforce drawn from over 50 nations. For further information, please visit [www.sunpharma.com](http://www.sunpharma.com) and follow us on [LinkedIn](#) & [X](#) (Formerly Twitter).

### **Contacts: Sun Pharma**

#### **Investors:**

Dr. Abhishek Sharma  
Tel + 91 22 4324 4324, Ext 2929  
Tel Direct + 91 22 43242929  
**Mobile** + 91 98196 86016  
**E mail** [abhi.sharma@sunpharma.com](mailto:abhi.sharma@sunpharma.com)

#### **Media:**

Gaurav Chugh  
Tel +91 22 4324 4324, Ext 5373  
Tel Direct +91 22 4324 5373  
**Mobile** +91 98104 71414  
**E mail** [gaurav.chugh@sunpharma.com](mailto:gaurav.chugh@sunpharma.com)